Our client, Hummingbird Bioscience, has received regulatory authorisation to initiate clinical trials for their SARS-CoV-2-targeted antibody, HMBD-115. Developed with partners in Singapore and the US, the commencement of trials for HMBD-115 is a significant milestone for the company, who have been working on an antibody therapy for COVID-19 since the emergence of the disease. Early read-out of the ongoing Phase I/II clinical trial of HMBD-115 is expected in December 2020, and a Phase III trial is scheduled for the end of 2020.
Neutralizing antibodies to SARS-CoV-2 are promising therapeutics for COVID-19, and offer an important treatment option in the absence of an effective vaccine, and for at-risk patients who may respond poorly to a vaccine. Pre-clinical studies have shown that HMBD-115 dramatically lowers circulating infectious virus and reduces inflammatory immune responses, which are a feature of severe disease.
Learn more about HMBD-115 at Hummingbird Bioscience's website.
Hummingbird Bioscience, founded in 2015 in Singapore, is a clinical-stage biotech company that uses systems biology and data science to better understand disease mechanisms and how to treat these, through the development of rationally engineered bio-therapeutics.
Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.
We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany. We’d love to hear from you, so please get in touch.
Sign up to Forward: news, insights and features from Mewburn Ellis
Copyright © 2023 Mewburn Ellis. All rights reserved. Terms and Conditions & Online Privacy